Meta Acquires AI Startup Manus to Expand Advanced AI Capabilities Across Platforms 
Boeing Secures $8.6 Billion Pentagon Contract for F-15 Jets for Israel 
ByteDance Plans Massive AI Chip Spending Boost as Nvidia Demand Grows in China 
Nike Stock Rises After CEO Elliott Hill Buys $1 Million in Shares 
Lockheed Martin Secures $92.8M AEGIS Sustainment Contract from U.S. Navy 
Australia’s Modern Gold Rush: Hobby Prospectors Flock to Victoria’s Golden Triangle 
Lockheed Martin Secures Nearly $500 Million in U.S. and Allied Defense Contracts 
BP’s Castrol Stake Sale Raises Debt Relief Hopes but Sparks Cash Flow Concerns 
Google Accelerates AI Infrastructure With Ironwood TPU Expansion in 2026 
Neuralink Plans Automated Brain Implant Surgeries and Mass Production by 2026 
Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China as Competition Intensifies 
Anghami Stock Soars After Strong H1 2025 Results, Revenue Nearly Doubles on OSN+ Integration 
L&F Tesla Battery Supply Deal Value Drops Sharply Amid EV Market Slowdown 
Target Stock Rallies as Activist Interest Sparks Hopes for Strategic Change 
Vietnam’s EV Taxi Giant GSM Eyes Hong Kong IPO With $2–3 Billion Valuation 
SoftBank Completes $41 Billion OpenAI Investment in Historic AI Funding Round 
CAMBRIDGE, Mass., March 18, 2016 -- Mersana Therapeutics, Inc. today announced that it will present two posters, one of which includes data on its new preclinical immunoconjugate, at the 2016 American Association for Cancer Research (AACR) Annual Meeting being held April 16-20, 2016, at the Ernest N. Morial Convention Center in New Orleans, LA.
Details of the posters being presented are as follows:
Title: Optimization of Lead Antibody Selection for XMT-1522, a Novel, Highly Potent HER2-Targeted Antibody-Drug Conjugate
Abstract Number: 596
Poster Session: Therapeutic Antibodies, Section 27
Date: Sunday, April 17, 2016
Time: 1:00 p.m. – 5:00 p.m. CT
Presenter: Natasha Bodyak, Ph.D., M.B.A., Executive Director, Biology, Mersana Therapeutics
The abstract describes the discovery and characterization of the novel anti-HER2 antibody used in XMT-1522, a novel HER2-targeting therapy based on Mersana’s Fleximer® immunoconjugate technology that is highly active in low HER2-expressing tumors and is fully combinable with current HER2 antibody therapeutics.
Title: Discovery and Preclinical Development of a Highly Potent NaPi2b-Targeted Antibody-Drug Conjugate with Significant Activity in Patient-Derived Non-Small Cell Lung Cancer (NSCLC) Xenograft Models
Abstract Number: 1194
Poster Session: Growth Factor Receptors and Surface Antigens as Therapeutic Targets, Section 15
Date: Monday, April 18, 2016
Time: 8:00 a.m. – 12:00 p.m. CT
Presenter: Natasha Bodyak, Ph.D., M.B.A., Executive Director, Biology, Mersana Therapeutics
XMT-1536, Mersana’s second preclinical candidate, is a highly potent anti-NaPi2b immunoconjugate comprised of an average of 15 auristatin molecules conjugated to XMT-1535, a novel humanized anti-NaPi2b antibody, via the Dolaflexin™ antibody-drug conjugate platform.
For more information about the AACR Annual Meeting, visit http://www.aacr.org/.
About Mersana Therapeutics
Mersana Therapeutics is advancing a proprietary pipeline of targeted oncology therapeutics leveraging its game-changing Fleximer® immunoconjugate technology. Mersana's first product candidate XMT-1522 has the potential to address significant unmet needs and improve patient outcomes in multiple oncology indications. Fleximer-based immunoconjugate molecules have been shown to have superior efficacy, including with targets previously considered not amenable to antibody-drug conjugate approaches. Mersana has collaborations utilizing Fleximer technology with Takeda, Merck KGaA, and Asana BioSciences. For more information, please visit www.mersana.com.
Media Contact 6 Degrees Tony Plohoros [email protected] (908) 591-2839 Investors Contact Stern Investor Relations, Inc. Jesse Baumgartner [email protected] (212) 362-1200
